AI Patent Analysis Toolkit
PatentAgility
by KellDann

Examiner Kyle T Rega

Examiner Kyle T Rega appears to be about average relative to their peer examiners. Their lifetime grant ratio is 32.7%, they average 1.89 office actions per granted patent, and their rejection profile is dominated by ยง103.

Difficulty vs AU About Average
Difficulty vs Group About Average
Difficulty vs TC About Average
Difficulty vs USPTO About Average
Average OA / Grant 1.89
Export
Word PDF

Create account to export.

Examiner Details

Observed Examiner Years
5 years (2022-2026)
Phone
(571) 272-2073
Predicted Supervisor
Neil Hammell
Supervisor Phone
(571) 270-5919
Tech Center
1600 - Biotechnology and Organic
Group
1630 - Stem Cells and Nucleic Acid Related Therapy

Metrics

Applications Evaluated
168
Granted Applications
55
Non-Granted Applications
113
Avg OA / Grant
1.89
Last OA Observed
June 2026 (1 months ago)
Art Units Seen
1636
Work Groups Seen

Context Comparison

Scope Examiners Lifetime Grant Ratio Avg OA / Grant
This Examiner 1 32.7% 1.89
Art Unit 30 37.9% 2.20
Group 245 37.7% 2.18
Tech Center 1,365 38.5% 2.02
USPTO 16,347 53.5% 1.98

Grant Timeline

0.0% 25.0% 50.0% 75.0% 100.0% 2022 2023 2024 2025 2026
Shaded region marks the last two observed years, where grant outcomes may lag due to recency.
Year Applications Granted Grant Rate
No observed data before 2022; examiner may not yet have been active in the available dataset.
2022 2 1 50.0%
2023 28 15 53.6%
2024 41 26 63.4%
2025 42 13 31.0%
2026 55 0 0.0%

55 family-cache-validated grants; 0 OA-only grant signals.

Rejection Timeline

OA # Office Actions § 101 Percentage § 102 Percentage § 103 Percentage § 112 Percentage
1 171 2.9% 6.4% 58.5% 4.7%
2 104 2.9% 9.6% 57.7% 7.7%
3 43 4.7% 14.0% 51.2% 9.3%
4 21 0.0% 4.8% 81.0% 4.8%
5 13 0.0% 7.7% 69.2% 7.7%
6 8 0.0% 12.5% 62.5% 0.0%
7 5 0.0% 20.0% 60.0% 20.0%
8 1 0.0% 100.0% 0.0% 0.0%

§ 101 Yearly Trend

2024: AI Examples
2025: Aug. Memo
0.0%
2022
3.0%
2023
0.0%
2024
3.9%
2025
5.2%
2026

Each bar shows the share of this examiner's observed office actions in that year that included a § 101 rejection.